RWD92 Evaluation of Second and Third Generation Tyrosine Kinase Inhibitor As First-Line Therapy for Non–Small-Cell Lung Cancer Patients: A Multi-Institutional Study in Taiwan
Abstract
Authors
Y.W. Cheng K.C. Chang H.Y. Chen Y.F. Fang